Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study

References

• Ryszkowska A, Gladysz A, Inglot M, Molin I. [Prevalence of anti-HAV antibodies in selected groups of children]. Przegl Epidemiol 2000; 54(3-4):375-83; PMID:11349601
   PubMedGoogle Scholar
• Liu XE, Chen HY, Liao Z, Zhou Y, Wen H, Peng S, Liu Y, Li R, Li J, Zhuang H. Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study. J Infect Dis 2015; 212(8):1232-6; PMID:25969561; http://dx.doi.org/10.1093/infdis/jiv213
   PubMed Web of Science ®Google Scholar
• McIntyre N. Clinical presentation of acute viral hepatitis. Br Med Bull 1990; 46(2):533-47; PMID:2116216
   PubMed Web of Science ®Google Scholar
• Zago-Gomes MP, Stantolin GC, Perazzio S, Aikawa KH, Gonçalves CS, Pereira FE. Prevalence of anti-hepatits A antibodies in children of different socioeconomic conditions in Vila Velha, ES. Rev Soc Bras Med Trop 2005; 38(4):285-9; PMID:16082472; http://dx.doi.org/10.1590/S0037-86822005000400001
   PubMed Web of Science ®Google Scholar
• Forbes A, Williams R. Increasing age–an important adverse prognostic factor in hepatitis A virus infection. J R Coll Physicians Lond 1988; 22(4):237-9; PMID:3230539
   PubMedGoogle Scholar
• Forbes A, Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br Med Bull 1990; 46(2):303-18; PMID:2198989
   PubMed Web of Science ®Google Scholar
• Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 1993; 18 Suppl 2:S11-4; PMID:8182265; http://dx.doi.org/10.1016/S0168-8278(05)80371-X
   PubMed Web of Science ®Google Scholar
• Collier MG, Khudyakov YE, Selvage D, Adams-Cameron M, Epson E, Cronquist A, Jervis RH, Lamba K, Kimura AC, Sowadsky R, et al. Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: an epidemiological case study. Lancet Infect Dis 2014; 14(10):976-81; PMID:25195178; http://dx.doi.org/10.1016/S1473-3099(14)70883-7
   PubMed Web of Science ®Google Scholar
• Ishii K, Kiyohara T, Yoshizaki S, Kawabata K, Kanayama A, Yahata Y, Takahashi T, Kinoshita H, Saitou T, Sunagawa T, et al. Epidemiological and genetic analysis of a 2014 outbreak of hepatitis A in Japan. Vaccine 2015; 33(45):6029-36.
   Web of Science ®Google Scholar
• Cao J, Bi S, Meng Q, Shen L, Zheng H, Zhang Y. Genotyping of acute hepatitis a virus isolates from China, 2003-2008. J Med Virol 2011; 83(7):1134-41; PMID:21520140; http://dx.doi.org/10.1002/jmv.22086
   PubMed Web of Science ®Google Scholar
• Wang XY, Xu ZY, Ma JC, von Seidlein L, Zhang Y, Hao ZY, Han OP, Zhang YL, Tian MY, Ouyang PY, et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007; 25(3):446-9; PMID:16949710; http://dx.doi.org/10.1016/j.vaccine.2006.08.004
   PubMed Web of Science ®Google Scholar
• Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W. Development, production, and postmarketing surveillance of hepatitis A vaccines in China. J Epidemiol 2014; 24(3):169-77; PMID:24681843; http://dx.doi.org/10.2188/jea.JE20130022
   PubMed Web of Science ®Google Scholar
• Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011; 83(11):1885-91; PMID:21915861; http://dx.doi.org/10.1002/jmv.22200
   PubMed Web of Science ®Google Scholar
• Jiang WP, Chen JT, Wang X, Wang YL, Liu Y, Chen WY, Xu WG, Qiu YZ, Yin WD. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. Vaccine 2008; 26(18):2297-301; PMID:18395305; http://dx.doi.org/10.1016/j.vaccine.2007.11.008
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, Loutan L. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010; 82(10):1629-34; PMID:20827757; http://dx.doi.org/10.1002/jmv.21883
   PubMed Web of Science ®Google Scholar
• Hens N, Habteab GA, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014; 32(13):1507-13; PMID:24508042; http://dx.doi.org/10.1016/j.vaccine.2013.10.088
   PubMed Web of Science ®Google Scholar
• Lopez EL, Contrini MM, Mistchenko A, Kieffer A, Baggaley RF, Di Tanna GL, Desai K, Rasuli A, Armoni J. Modeling the Long-term Persistence of Hepatitis A Antibody After a Two-Dose Vaccination Schedule in Argentinean Children. Pediatr Infect Dis J 2015; 34(4):417-25; PMID:25764099; http://dx.doi.org/10.1097/INF.0000000000000605
   PubMed Web of Science ®Google Scholar
• Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of Longitudinal Data. Oxford Statistical Science Series. 2009: Oxford University Press.
   Google Scholar
• Fitzmaurice GM, L.N.W.J., Applied Longitudinal Analysis. II ed. 2011: Hoboken, New Jersey: John Wiley & Sons, Inc.
   Google Scholar
• Desai K, Coudeville L, Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine 2012; 30(15):2510-5; PMID:22342547; http://dx.doi.org/10.1016/j.vaccine.2012.02.005
   PubMed Web of Science ®Google Scholar
• Overbosch D, Peyron F, Picot N, Varichon JP, Dumas R, Chambonneau L, Weber F. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J Travel Med 2005; 12(6):319-26; PMID:16343383; http://dx.doi.org/10.2310/7060.2005.12604
   PubMed Web of Science ®Google Scholar
• Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44(4):446-51; PMID:7897379; http://dx.doi.org/10.1002/jmv.1890440425
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, Bell BP, McMahon BJ. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008; 198(12):1776-82; PMID:18976095; http://dx.doi.org/10.1086/593335
   PubMedGoogle Scholar
• Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011; 83(11):1885-91; PMID:21915861; http://dx.doi.org/10.1002/jmv.22200
   PubMed Web of Science ®Google Scholar
• Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother 2012; 8(3):323-7; PMID:22327499; http://dx.doi.org/10.4161/hv.18617
   PubMed Web of Science ®Google Scholar
• Andre F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 2002; 1(1):9-23; PMID:12908508; http://dx.doi.org/10.1586/14760584.1.1.9
   PubMedGoogle Scholar
• Bailleux F, Coudeville L, Kolenc-Saban A, Bevilacqua J, Barreto L, André P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008; 26(31):3903-8; PMID:18555563; http://dx.doi.org/10.1016/j.vaccine.2008.04.089
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68(4):489-93; PMID:12376955; http://dx.doi.org/10.1002/jmv.10244
   PubMed Web of Science ®Google Scholar
• Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 1997; 15(6-7):612-5; PMID:9178459; http://dx.doi.org/10.1016/S0264-410X(96)00242-3
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974; 19:716-723; http://dx.doi.org/10.1109/TAC.1974.1100705
   Web of Science ®Google Scholar
• GE S. Estimating the dimension of a model. Ann Statist 1978; 6:461-464; http://dx.doi.org/10.1214/aos/1176344136
   Web of Science ®Google Scholar